Poloamer 188 as an Adjunct in Prolonged Hypotensive Resucitation

Abstract

Despite tremendous efforts, exsanguinations remains a leading cause of deaths (approximately 40 %) in both civilian and military trauma. A subset of injured soldiers develop decompensated shock that requires early interventions if they are to survive. This project is testing the ability of a new drug, purified poloxamer 188 (P188), to increase survival and reduce inflammation and organ injury resulting from prolonged periods of hypotensive resuscitation in a model specified by the ARMY. The results are strongly positive. Addition of P188 to standard therapy with Hextend significantly improved survival (p=0.002)and reduced fluid requirements (p=0.0002) in rats subjected to prolonged hypotensive resuscitation. These studies are being followed up with studies with more complex injuries and with uncontrolled hemorrhage in rats, rabbits and pigs.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Jul 01, 2017
Accession Number
AD1039581

Entities

People

  • Ernest Gonzalez
  • Frederick Moore
  • Robert Hunter
  • Rongzhen Zhang

Organizations

  • University of Texas Health Science Center at Houston

Tags

Communities of Interest

  • Biomedical

DTIC Thesaurus Topics

  • Biomedical Research
  • Cardiovascular Physiological Phenomena
  • Computers
  • Data Storage Systems
  • Department Of Defense
  • Experimental Design
  • Heart Rate
  • Hemorrhage
  • Hemorrhagic Shock
  • Inflammation
  • Information Operations
  • Infusions
  • Resuscitation
  • Standards
  • Statistical Analysis
  • Survival
  • Therapy

Fields of Study

  • Medicine

Readers

  • Trauma Surgery or Emergency Medicine.